anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To enable the production of a water-base copolymer dispersion in a medium essentially comprising water by subjecting a mixture comprising a water-soluble N-vinylated nonionic monomer having a specified water solubility and a major amt. of a hydrophobic monomer having a specified water solubility to free-radical, water-base emulsion polymn. SOLUTION: A monomer mixture comprising 10-70 wt.% N-vinylated nonionic monomer having a water solubility higher than 60 g/l at 25 deg.C and 30-90 wt.% monoethylenically unsatd. hydrophobic monomer having a water solubility lower than 60 g/l at 25 deg.C is polymerized. An N-vinyllactam is an esp. advantageous N-vinylated monomer. A water-soluble azo compd., an alkali or ammonium salt of peroxodisulfuric acid, and hydrogen peroxide are examples of an esp. advantageous polymn. initiator. Pref., at least 70% of the initiator is continuously fed in the form of a water soln. or a water-alcohol soln.
PURPOSE: A composition containing DKK3 protein or a polynucleotide encoding the protein for inducing cell autophagy is provided to treat or relieve diseases caused by abnormal cells or proteins. CONSTITUTION: A composition for inducing cell autophagy contains DKK3 protein or a polynucleotide encoding the protein as an active ingredient. DKK3 includes autophagosome formulation in cells. The protein or polynucleotide is derived from human. The protein has an amino acid sequence of sequence number 1. The polynucleotide encoding DKK3 has a nucleic acid sequence of sequence number 2. A polynucleotide encoding DKK3 contains an expression vector for intracellular transduction. A pharmaceutical composition for treating diseases related to autophagy contains the protein or polynucleotide as an active ingredient.
Sleep disruption is prevalent in frontline healthcare workers (HCWs), of which more than 30% are physicians and nurses. The ongoing COVID-19 crisis has caused decreasing well-being and worsening mental health. Frontline HCWs involved in the management of patients with COVID-19 are nearly 3 times more likely to experience insomnia than anxiety or depression. It can have direct consequences on cognitive and emotional functioning and well-being, which impacts the safety of the patients. Insomnia is a health problem that may be appropriately treated with a less resource-intensive solution. Hypnotics can be considered for short-term use for severe insomnia but it is not free of psychological and/or physical dependence, tolerance, substance misuse, and sleepiness. Therefore, non-pharmacological sleep therapies such as CBTi may be advantageous for improving sleep health, HCW wellness, and in preventing burnout.

Cognitive Behavioral Therapy for insomnia (CBTi) is currently a first-line therapy for adults with sleep disorders including insomnia and other sleep health disruptions. The principles and specific elements of CBTi include stimulus control, sleep hygiene, relaxation therapy, cognitive re-appraisal, and sleep restriction techniques. Delivering CBTi to frontline HCWs is associated with significant barriers including the limited availability of trained sleep therapists and the high cost of receiving face-to-face treatment. Digital CBTi can be easily accessed while maintaining physical distancing, and is less resource intensive than traditional CBTi, while providing symptom self-management and ongoing coach-tailored feedback. Recently, digital CBTi (Sleepio™, Big Health Ltd., London, UK) was made available free of charge to over 1 million frontline COVID-19 HCWs in the United Kingdom's National Health Service for the duration of the COVID-19 pandemic. Indeed, CBTi has already been shown to be effective for patients with insomnia in the general population, but it has not been evaluated amongst HCWs during a pandemic. We propose a national RCT amongst frontline HCWs taking care of patients during the COVID19 era to determine the effect of a digital CBTi program (SleepioTM) on their sleep health, mental health, wellness domains, and overall HRQL.
Anesthesia will be induced with inhaled sevoflurane which will be discontinued once IV access is obtained and the airway is secured with an endotracheal tube. Patients will receive remifentanil loading dose of 1mcg/kg over 1 min followed by an infusion (0.05-0.5 mcg/kg/min) and dexmedetomidine load at 1mcg/kg over 10 mins followed by and infusion (0.2-0.7 mcg/kg/hr) A caudal block with 0.2% ropivacaine will be performed in all patients for intraoperative and postoperative pain control.
A pharmaceutical composition for the sublingual delivery of an opioid comprising an opioid and ethanol, wherein the composition is comprised within a container such that the material of the container that is in contact with the composition is cyclic olefin copolymer (COC). Preferably, the opioid is methadone and is not fentanyl. The composition may further include glycerol. Preferably the container comprises a delivery device to dispense the composition in a single discharge as a spray. The delivery device may further include seals and/or plungers formed from bromobutyl polymer. The composition is preferably for use in the treatment of pain, inducing or maintaining anaesthesia, treating opioid dependence, treating anxiety, treating cough or treating diarrhoea.
OBJECTIVE: Given the ubiquity and severity of postoperative pain following spine surgery, developing adequate pain management modalities is critical. Transcutaneous electrical nerve stimulation (TENS) is a promising noninvasive modality that is well studied for managing postoperative pain following a variety of surgeries, but data on using TENS for pain management in the acute postoperative period of spine surgery are limited. Therefore, this review aimed to recapitulate the existing evidence for the use of TENS in postoperative pain management for spine surgery and explore the potential of this modality moving forward.
METHODS: A scoping review was conducted according to 2020 PRISMA guidelines. Two independently operating reviewers then conducted a systematic search of PubMed, Embase, and Scopus databases to identify studies that reported the use of TENS for the treatment of acute postoperative pain following spine surgery. The following data were abstracted from included studies: study type, sample size, demographics, surgery details, comparison group, assessment parameters, timing of postoperative assessment, TENS technical characteristics, relevant findings, length of hospital stay, complications with TENS, and notable limitations.
RESULTS: Nine hundred thirty-two publications were screened, resulting in 6 studies included in this review, all of which were prospective clinical trials. The publication dates ranged from 1980 to 2011. Spine surgery types varied; the most common was posterior lumbar interbody fusion. No studies evaluated pain control in cervical- or thoracic-only surgeries. All 6 studies evaluated the level of postoperative pain directly. Five of the 6 studies that directly examined postoperative pain reported lower levels of pharmacological analgesia usage in the TENS groups compared with controls, with 4 of these studies reporting this difference as statistically significant. Length of hospital stay was evaluated in 2 studies, both of which reported decreases in mean length of stay, but these differences were not significant. Notably, every study reported distinct TENS administration parameters while also reporting similar results.
CONCLUSIONS: This review concludes that TENS is effective at reducing postoperative pain in spine surgery. Further investigation is needed regarding the optimal settings for TENS administration, as well as efficacy in the thoracic and cervical spine.
Assessments for bladder function will be conducted pre-training and following 80 sessions of locomotor training. Locomotor training consists of body-weight supported stepping on a treadmill for one hour.
The present invention discloses umbilicus pasting medicine powder for treating prostate diseases, which relates to an external medicine preparation for treating prostate diseases by an umbilicus pasting method. The umbilicus pasting medicine powder for treating prostate diseases is prepared from pangolin, musk, giant knotweed rhizome, prism tuber, cutis erinacei, white pepper, radix althaeae roseae, Huxi, water plantain, herba dianthi and root of straight ladybell. When used, the umbilicus pasting medicine powder is pasted in umbilicus, medicinal cotton and porous adhesive tapes are covered, and seven days is a treating course. The umbilicus pasting medicine powder for treating prostate diseases has the functions of restoring channels, activating collaterals, dissipating binds, dispersing swelling, clearing dampness, promoting diuresis, clearing heat, dissipating blood stasis for freeing strangury, opening striae, regulating water passages and promoting urination for freeing strangury. The present invention can reduce prostate hyperplasia, lightens symptoms, such as lower abdominal distension, frequent micturition, urgent micturition, painful urination, etc., and has curative effect on treating chronic cystitis. The present invention has no toxic or side effect. One hundred patients with prostatitis, etc. are clinically observed, 49 patients are cured by the umbilicus pasting medicine powder for treating prostate diseases, and the cure rate is 49 %; 27 patients are improved, and the improving rate is 27 %; the present invention is effective to 19 patients, and the effective rate is 19 %; the present invention is ineffective to 5 patients, and the ineffective rate is 5 %.
NEW MATERIAL:An immunosuppressive factor having the following physical and chemical properties. Molecular weight: about 79,000 (gel filtration method). Color reaction: positive in Lowry reaction and anthrone reaction. Enzyme stability: not deactivated by trypsin treatment 37 deg.C for 2 hours. Temperature stability: stable by treatment at 56 deg.C for 30 minutes and unstable by treatment at 100 deg.C for 1 minute. pH stability: unstable at pH 2 and stable at pH 10. Isoelectric point: about 5.4. USE:An immunosuppressive agent free from cytotoxin. PREPARATION:A cell derived from mouse placenta is cultured and an ummunosuppressive factor is collected from the culture mixture.
Patients' inclusion criteria: (i) age≥18 years; (ii) time post-injury≥28 days. Exclusion criteria will be: (i) large craniectomy interfering with EEG recording; (ii) unstable clinical conditions; (iii) presence of ophthalmic disorders, or central or peripheral impairments in eyelid motility on clinical evaluation; (iv) administration of sedative medication in the previous 24h; (v) previous history of neurological or psychiatric diseases; (vi) written informed consent by patient or, where necessary, by primary caregiver.
Spleen-preserving distal pancreatectomy offers an alternative surgical approach to the traditional distal pancreatectomy combined with splenectomy for removing benign and low-grade malignant lesions in the distal pancreas, avoiding complications associated with splenectomy. This procedure can be accomplished either by resecting and ligating the splenic vessels (Warshaw technique) or by preserving them (Kimura technique). Currently, the widespread use of minimally invasive surgery has established laparoscopic and robotic approaches for spleen-preserving distal pancreatectomy as valid and safe options for treating such conditions. Our protocol aims to describe how the Warshaw and Kimura techniques of spleen-preserving distal pancreatectomy can be performed robotically. The first patient is a 36-year-old female with a neuroendocrine tumor (NET) in the pancreatic body who underwent a spleen-preserving distal pancreatectomy with the ligation of the splenic vessels (WT). The second patient is a 76-year-old male with chronic pancreatitis presenting with a dilated main pancreatic duct in the tail of the pancreas who underwent a spleen-preserving distal pancreatectomy with a vessel-preserving approach (KT).
In a randomized, double-blind, and cross-over fashion, the participants will be exposed to clean air, ultrafine particles, or ultrafine particles and ozone in an exposure chamber. The investigators will determine blood pressure, heart rate, respiration as well as cardiac output and directly record sympathetic vasomotor tone using the microneurography technique. To elucidate the underlying mechanisms through which particles and ozone affect the autonomic nervous system, the investigators will assess the local and systemic inflammatory response as well as the changes in neurotrophic factors in sputum and blood. In addition, the activation of inflammatory cells in sputum and blood will be analyzed at different points in time after exposures. Changes in sympathetic activity will be correlated with the degree of airway inflammation and oxidative stress assessed in induced sputum and blood. This study will provide important insight in the mechanisms through which air pollution, particularly ultrafine particle exposure, increases cardiovascular risk in human subjects and generate a human model for mechanistic and therapeutic studies.
Liquid preparations of tribromoethyl alcohol which are stable when heated are obtained by incorporating with the alcohol one or more substances of the following kinds, viz. acid amides (other than formamide) or substitution products thereof, higher primary monohydric alcohols, higher polyhydric alcohols, ethers and/or esters of mono- or polyhydric alcohols, acetals, ketones, hydroxyketones, ureas, urethanes and cyclic acid amides.  The esters of the alcohols may be derived from substituted carboxylic acids, and the esters and ethers of the polyhydric alcohols may contain, in addition to free hydroxyl groups, various residues combined as ethers or esters or both.  The following substances are specifically referred to, viz., acetamide, butyramide, mono- or dimethylacetamide, diethylacetamide, butanol, a -methylheptanol, butyleneglycol, glycerin diethyl ether, glycol monoethyl ether, glycol monobutyl ether, glycol-a -methyl-ether-b -acetic acid ester, dioxane, ethyl acetate, lactic acid ethyl ester, glycerin diacetate, methyl ethyl ketone, methylene glycol diethyl ether (CH2.(OC2H5)2), carbamic acid ethyl ester, dimethylcarbamic acid ethyl ester, dimethylcarbamic acid methyl ester, diketopiperazine, and mixtures of acetamide and methylacetamide, of carbamic acid methyl and ethyl esters, and of acetamide, sarcosin anhydride and glycol monoethyl ether. Specifications 302,337, 317,327, [both in Class 2 (iii), Dyes, &c.], and 338,985, [Class 81 (i), Disinfecting &c.], are referred to.ALSO:Liquid preparations of tribromoethyl alcohol which are stable when heated are obtained by incorporating therewith one or more substances of the following kinds, viz.: acid amides (other than formamide) or substitution products thereof, higher primary monohydric alcohols, higher polyhydric alcohols, ethers and/or esters of mono- or polyhydric alcohols, acetals, ketones, hydroxyketones, ureas, urethanes and cyclic acid amides.  The esters of the alcohols may be derived from substituted carboxylic acids, and the esters and ethers of the polyhydric alcohols may contain, in addition to free hydroxyl groups, various residues combined as ethers or esters or both.  The following substances as additions to the tribromoethyl alcohol are specifically mentioned, viz.: acetamide, butyramide, mono- or dimethyl acetamide, diethyl p  acetamide, butanol, and methyl keptanol, butylene glycol, glycerin diethyl ether, glycolmonoethyl ether, glycolmonobutyl ether, glycol-a -methyl-ether-b -acetic acid ester, dioxane, ethyl acetate, lactic acid ethyl ester, glycerin diacetate, methyl ethyl ketone, methylene-glycol-diethyl ether (formaldehyde diethyl acetal), carbamic acid ethyl ester, dimethyl carbamic acid methyl ester, diketopiperazine and mixtures of acetamide and methylacetamide, of carbamic acid, methyl and ethyl esters, and of acetamide, sarcosin anhydride, and glycol monoethyl ether. Specifications 317,327 and 338,985, [both in Class 81 (i), Disinfecting &c.], are referred to.
All children screened for SARS-CoV-2 and presenting to participating sites will be enrolled in this study. Children who are eventually test-positive for SARS-CoV-2 will be considered the exposed group in this study. These children will have exactly the same prospective follow-up as the other group.
[S U M M A R Y] Many miRNA-disease association prediction models incorporate Gaussian interaction profile kernel similarity (GIPS). However, the GIPS fails to consider the specificity of the miRNA-disease association matrix, where matrix elements with a value of 0 represent miRNA and disease relationships that have not been discovered yet. To address this issue and better account for the impact of known and unknown miRNA-disease associations on similarity, we propose a method called vector projection similarity-based method for miRNA-disease association prediction (VPSMDA). In VPSMDA, we introduce three projection rules and combined with logistic functions for the miRNA-disease association matrix and propose a vector projection similarity measure for miRNAs and diseases. By integrating the vector projection similarity matrix with the original one, we obtain the improved miRNA and disease similarity matrix. Additionally, we construct a weight matrix using different numbers of neighbors to reduce the noise in the similarity matrix. In performance evaluation, both LOOCV and 5-fold CV experiments demonstrate that VPSMDA outperforms seven other state-of-the-art methods in AUC. Furthermore, in a case study, VPSMDA successfully predicted 10, 9, and 10 out of the top 10 associations for three important human diseases, respectively, and these predictions were confirmed by recent biomedical resources.
BACKGROUND: Somatosensory evoked potentials (SEPs) are highly specific predictors of poor prognosis in hypoxic-ischemic coma when cortical responses (N20s) are absent. However, bilateral N20 presence is nonspecific for good outcomes. High-frequency oscillations (HFOs) in the SEP waveform predict neurologic recovery in animals, but clinical applications are poorly understood. We sought to develop a clinical measure of HFOs to potentially improve detection of good outcomes in coma.
MATERIALS AND METHODS: We collected SEP waveform data from all comatose inpatients (GCS<=8) who underwent neurologic prognostication from 2020 to 2022 at Johns Hopkins Hospital. We developed a novel measure - HFO evoked to spontaneous ratios (HFO-ESRs) - and applied this to those patients with bilaterally present N20s using both standard univariate classification and cubic kernal vector machine (SVM) models to predict the last documented in-hospital Glasgow Coma Scale (GCS) prior to discharge or death.
RESULTS: Of 58 total patients, 34 (58.6%) had bilaterally present N20s. Of these, 14 had final GCS>=9, and 20 had final GCS<=8. Mean age was 52 (+/- 17) years, 20.1% female. Etiologies of coma were primarily global hypoxic-ischemic brain injury (79.4%), intracranial hemorrhage (11.8%), and traumatic brain injury (2.9%). In univariate classification, the addition of averaged HFO-ESRs to bilaterally present N20s predicted final GCS>=9 with 68% specificity. The SVM model further improved specificity to 85%.
CONCLUSIONS: In this pilot investigation, we developed a novel clinical measure of SEP HFOs. Incorporation of this measure may improve the specificity of the SEP to predict in-hospital GCS outcomes in coma, but requires further validation in specific neurologic injuries and with longitudinal outcomes.
This is an open label exploratory study of the immunologic efficacy and safety of an FDA-approved Hepatitis B vaccine called Heplisav-B. It will be used in patients treated with long term immunosuppressive drug therapy. The patients will be given two doses of Heplisav-B, the first delivered at the baseline visit and the second at week 4. Antibody levels against the Hepatitis B virus will be measured at baseline and at weeks 4, 8, 12, 24 and 60. The proportion of those patients with protective antibody levels will be compared with non-immune compromised patients receiving the same dosing schedule. Patients who fail to demonstrate protective levels of antibodies at week 8 will be given a third booster dose at week 12, and all patients will be followed to week 60.

This research is being done because current alternative hepatitis B vaccines produce lower levels of antibody to hepatitis B, and the level of antibody can be important in the prevention of the virus coming back. However, administration of Heplisav-B has been associated with higher levels of protective antibody in healthy individuals, people with diabetes, and people with kidney disease. It is hoped that the same beneficial effect of higher antibody level will also occur in patients who take an immune suppressing medicine to treat underlying inflammatory disorder (either arthritis, colitis, or chronic skin inflammation), chemotherapy for cancer, or anti-rejection therapy for liver transplantation.
This is a worldwide, multicenter, non-interventional, retrospective study. The study will consist of 2 components. The first component involves local lab rescoring of qualified historical HER2 fixed tissue immunohistochemistry (IHC) stained slides (preferably using Ventana 4B5 assay) at sites (post-training) for mBC patients previously identified as HER2-neg, and independent central retesting of HER2 status using Ventana 4B5 assay for any enrolled patients with available archived tissue samples at designated central laboratories. Local lab rescoring and independent central retesting/local lab retesting will be conducted blinded of historical HER2 IHC scores.

The second component involves linking the rescored IHC status to the patient medical record either through registry databases or patient chart review. Such information will be used to describe the patient demographics, histopathological features, clinical presentation, and treatment patterns following mBC diagnosis, and clinical outcomes in real-world settings for all patients with HER2 scores of 0, \>0 and \< 1+, and 1+2+/ISH- (HER2 low). The clinicopathological and other relevant BC biomarker information will also be examined based on historical biomarker testing results and/or new testing conducted as part of this study.
This arm involved high intensity muscle strength training at 75% maximum inspiratory pressure (MIP). Training took place for 4 weeks, 5 days a week. Each daily session involved 5 sets of breathing exercises that required participants to take deep breaths (i.e., inspire) using use a breathing device. Settings on the breathing device were determined by obtaining the individual's maximal inspiratory pressure (MIP)using a specialized breathing gauge. The MIP was determined at the beginning of each week and the training device was adjusted and set at 75% MIP. Exercises took place in home setting, with weekly visit by staff. Participants kept daily exercise log.